z-logo
open-access-imgOpen Access
Selective Degradation of GSPT1 by Cereblon Modulators Identified via a Focused Combinatorial Library
Author(s) -
Chelsea E. Powell,
Guocheng Du,
Jianwei Che,
Zhixiang He,
Katherine A. Donovan,
Hong Yue,
Eric S. Wang,
Radosław P. Nowak,
Tinghu Zhang,
Eric S. Fischer,
Nathanael S. Gray
Publication year - 2020
Publication title -
acs chemical biology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.899
H-Index - 111
eISSN - 1554-8937
pISSN - 1554-8929
DOI - 10.1021/acschembio.0c00520
Subject(s) - cereblon , chemistry , computational biology , ubiquitin ligase , peptoid , chemical library , chemical biology , small molecule , pomalidomide , lenalidomide , biochemistry , biology , ubiquitin , multiple myeloma , gene , peptide , immunology
Cereblon (CRBN) is an E3 ligase adapter protein that can be reprogrammed by imide-class compounds such as thalidomide, lenalidomide, and pomalidomide to induce the degradation of neo-substrate proteins. In order to identify additional small molecule CRBN modulators, we implemented a focused combinatorial library approach where we fused an imide-based CRBN-binding pharmacophore to a heterocyclic scaffold, which could be further elaborated. We screened the library for CRBN-dependent antiproliferative activity in the multiple myeloma cell line MM1.S and identified five hit compounds. Quantitative chemical proteomics of hit compounds revealed that they induced selective degradation of GSPT1, a translation termination factor that is currently being explored as a therapeutic target for the treatment of acute myeloid leukemia. Molecular docking studies with CRBN and GSPT1 followed by analogue synthesis identified a possible hydrogen bond interaction with the central pyrimidine ring as a molecular determinant of hit compounds' selectivity. This study demonstrates that a focused combinatorial library design, phenotypic screening, and chemical proteomics can provide a suitable workflow to efficiently identify novel CRBN modulators.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.
Having issues? You can contact us here